UPDATE: NeoGenesis in Drug-Discovery Deal With Schering-Plough | GenomeWeb

NEW YORK, Aug. 6 – NeoGenesis and Schering-Plough Corporation have partnered to discover small-molecule drug leads, the companies announced on Monday.

Under the deal, NeoGenesis will employ its Automated Ligand Identification System (ALIS) and its neoMorph compound library to help Schering-Plough discover a range of antiviral candidates. In exchange, the drug giant will outlay research and development funding as well as an undisclosed equity investment in NeoGenesis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.